Yes; bowel cancer that is found early is often cured, and surgery is the basis of that cure [1]. In the United States, 9 in 10 people whose cancer is still within the bowel are alive 5 years later; and when the cancer has reached nearby lymph nodes (stage 3), most people also survive with surgery followed by chemotherapy [2, 3]. Cancer that has spread to distant parts of the body is usually controlled rather than cured; but if it has reached only a few spots in the liver or lungs and all of them can be removed with surgery, some people are cured completely [1].
Key points
- The earlier, the better the chance of cure: in the United States, 9 in 10 people whose cancer is still only in the bowel are alive 5 years later [2].
- In stage 3, surgery followed by chemotherapy is the standard treatment; in a large study, about 7 in 10 people with stage 3 cancer who had this treatment were alive 6 years later [3].
- Stage 4 can sometimes be cured too: if the cancer has reached only a few spots in the liver or lungs and all of them are removed with surgery, about 3 to 4 in 10 carefully selected people are cured completely [1].
- Genetic testing of the tumour (MSI, and in advanced disease RAS and BRAF) shows both the outlook and the best treatment [5, 6].
- In rectal cancer, with treatment before surgery and close follow-up, about half of the people in one study still had their rectum 5 years later [10].
- Regular exercise after chemotherapy ends made the cancer less likely to come back in a large study [12].
Is colon cancer curable? What does "cure" mean?
Yes. According to the US National Cancer Institute, colon cancer that is still within the bowel is highly treatable and often curable [1]. A cure means treatment that aims to remove the cancer completely and stop it coming back. Surgery is the basis of this treatment, and about half of all people with colon cancer are cured with surgery [1].
Each person's chance depends above all on three things: how deep the cancer has grown into the bowel wall, whether it has reached the lymph nodes, and whether it has spread to distant parts of the body [1]. The result of the tumour's MSI test and the number of lymph nodes examined are also used to estimate the risk of the cancer coming back [5]. If the tumour has blocked the bowel or made a hole in it, or the CEA blood test was high before treatment, the disease is more serious [1]. Statistics come from thousands of patients and cannot say exactly what will happen to one person. Read more: What are cancer stages? and Can cancer be cured?
Colon cancer survival rate: how long do people live, by stage?
| Stage | What it means | About 30 years ago | Today |
|---|---|---|---|
| Only in the bowel | The cancer has not yet grown outside the bowel wall | Nearly 9 | 9 |
| Spread nearby | It has reached the lymph nodes or tissue next to the bowel | Nearly 7 | More than 7 |
| Spread far (stage 4) | It has reached distant places such as the liver or lungs | Fewer than 1 | 1 to 2 |
| All stages | All patients together | 6 | More than 6 |
Compared with people of the same age without cancer. The "Today" column covers people diagnosed between 2015 and 2021, and the "About 30 years ago" column people diagnosed between 1995 and 1997. For rectal cancer that has spread, today's figure is nearly 2 in 10 [2].
For bowel cancer that has spread, the chance of living 5 years has nearly doubled since the 1990s [2]. These numbers are averages of thousands of patients, come from people diagnosed several years ago and cannot predict one person's future [2]. To understand these statistics, read: How long do people with cancer live? What 5-year survival means.
Treatment and the chance of cure at each stage
- 1
Stages 0 and 1
The cancer is only in the inner layers of the bowel wall. Removing the polyp or tumour during a colonoscopy, or an operation to remove part of the bowel, is usually enough, and the chance of cure is very high [1].
- 2
- 3
Stage 3
The cancer has reached the lymph nodes next to the bowel. Treatment is surgery followed by chemotherapy [1, 5]. In a large study of people with stage 3 cancer, after surgery and 6 months of combination chemotherapy including the drug oxaliplatin, about 7 in 10 were alive 6 years later [3]. In people at lower risk, 3 months of chemotherapy with capecitabine tablets and oxaliplatin worked as well as 6 months and caused much less numbness in the hands and feet [4]. Chemotherapy is best started no later than 8 weeks after surgery [5].
- 4
Rectal cancer
In rectal cancer with high-risk features, chemotherapy and radiotherapy are given before surgery [11]. If the tumour disappears completely with this treatment, it is sometimes possible to keep the rectum without surgery, with close follow-up [10, 11]. See the section "Keeping the rectum and follow-up after treatment".
- 5
Stage 4 (spread)
Stage 4 colon cancer: can it be treated, and what is the life expectancy?
Stage 4 bowel cancer is not always beyond cure. In some people whose cancer has reached only the liver or lungs and who are carefully selected for surgery, surgery leads to a cure in about 3 to 4 in 10 [1]. If your liver is affected, ask whether your case has been discussed at a treatment team meeting (liver surgeon, oncologist and radiologist).
For most people with stage 4 disease, the aim of treatment is long-term control of the disease and a better life. In the United States today, 1 to 2 in 10 people with bowel cancer that has spread are alive 5 years later [2]. The most important step before treatment starts is genetic testing of the tumour, because it changes the type of treatment and its results [6]. Read more: What is stage 4 cancer and can it be treated? and What is metastasis?
How do tumour genetic tests change the chance of successful treatment?
- MSI-H or dMMR (a fault in the tumour's DNA repair system): immunotherapy works very well in this type [6]. In cancer that has spread, the immunotherapy drug pembrolizumab kept the disease under control for nearly twice as long as chemotherapy, with about a third of the severe side effects of chemotherapy [7]. With a combination of two immunotherapy drugs, nivolumab and ipilimumab, about 7 in 10 people had no growth of their cancer 2 years later; about 5 times as many as with chemotherapy [8].
- RAS mutation: if the RAS gene has a mutation, anti-EGFR drugs (cetuximab and panitumumab) do not work, and a different targeted drug is given with chemotherapy [6].
- BRAF V600E mutation: this type is more aggressive and has a worse outlook with the usual treatment [9]. In a large study, two targeted drugs, encorafenib and cetuximab, given with chemotherapy, nearly doubled how long people lived compared with the usual treatment [9].
Ask your doctor what these tests showed in your tumour. Read more: Bowel cancer with MSI-H or dMMR: immunotherapy instead of chemotherapy and Chemotherapy or targeted therapy?
Keeping the rectum and follow-up after treatment
In rectal cancer, if no trace of the tumour can be seen after chemotherapy and radiotherapy, the European guideline suggests close follow-up instead of surgery ("watch and wait") [11]. In one study, with this approach about half of the people still had their rectum 5 years later [10]. If the tumour comes back, it almost always does so within the first 2 years; and people whose tumour came back and who then had surgery stayed free of the disease as often as people whose tumour had not fully disappeared with the treatment before surgery and who had surgery straight away [10].
This is why follow-up matters so much with this approach: MRI, endoscopy and examination every 3 months for the first 2 years, then every 6 months [11]. For dMMR rectal cancer, the European guideline suggests immunotherapy with dostarlimab and, if the tumour disappears completely, follow-up without surgery [11].
After treatment for colon cancer too, regular check-ups and tests can find the cancer earlier if it comes back [1]. Read: What is cancer recurrence and how is it followed up? and What does a high CEA mean?
What improves the chance of successful treatment?
Regular exercise after chemotherapy
In a large study of people with colon cancer, a 3-year exercise programme started soon after chemotherapy made the cancer less likely to come back and seems to have helped people live longer too [12]. Talk to your treatment team before you start. Read: Exercise as treatment and Exercise during cancer treatment.
The tumour MSI test
An MSI or MMR test on the tumour sample is recommended [5, 11]. The result helps choose the treatment and also shows whether the family needs genetic counselling [5]. Read: Is cancer hereditary?
Chemotherapy on time and in full
If you need chemotherapy after surgery, it is best started within 8 weeks [5]. Report side effects early so that treatment is not interrupted. Read: Complete, on-time treatment without breaks.
Finding it earlier
Cancer that is still within the bowel has the best chance of cure [2]. Know the warning signs and start screening at the age your doctor recommends: Symptoms of bowel cancer and At what age is screening colonoscopy needed?
Frequently asked questions
How long do people with bowel cancer live?
It depends on the stage. In the United States, 9 in 10 people whose cancer is only in the bowel, more than 7 in 10 people whose cancer has reached the lymph nodes or nearby tissue, and 1 to 2 in 10 people whose cancer has spread are alive 5 years later [2]. These numbers are averages and cannot predict one person's future. Read about bowel cancer at a younger age: Bowel cancer in young adults.
What happens if bowel cancer is not treated?
Over time, bowel cancer can grow deeper into the bowel wall, reach the lymph nodes and spread to distant parts of the body; and each step lowers the chance of cure [1, 2]. Sometimes the tumour also blocks the bowel or makes a hole in its wall, which is a sign of more serious disease [1]. This is why treatment should not be delayed. Even when the cancer has spread, today's treatments control the disease and have helped people live longer [2, 9].
Is colon cancer cured for good? Can it come back?
Yes, many people are cured completely [1]. But in some people, especially when the cancer had reached the lymph nodes, it can come back; this is why chemotherapy after surgery and regular follow-up matter [1, 3]. In a large study, about 3 in 4 people with stage 2 or 3 cancer who had surgery and combination chemotherapy were free of the disease 5 years later [3].
Is stage 3 colon cancer curable?
Yes. Treatment is surgery followed by chemotherapy, and most people survive: in the United States, more than 7 in 10 people whose cancer has reached the lymph nodes or nearby tissue are alive 5 years later [2]. How long chemotherapy lasts (3 or 6 months) depends on the risk of the cancer coming back and the type of drugs [4, 5].
Can bowel cancer that has spread to the liver be cured?
Sometimes, yes. If the cancer has reached only the liver or lungs and all the tumours can be removed with surgery, about 3 to 4 in 10 carefully selected people are cured completely [1]. If surgery is not possible, medicines chosen according to the genetic test of the tumour control the disease [6]. Read more: What are liver metastases and can they be treated?; this is a different disease from cancer that starts in the liver itself: Is liver cancer curable?
Survival and treatment evidence by stage (for doctors)
For physicians
Population survival (SEER). 5-year relative survival for colorectal cancer diagnosed 2015–2021: all stages 65%, localised 91%, regional 74% and distant 15%; compared with 61%, 89%, 66% and 8% for diagnoses in 1995–1997. Distant colon 14% and distant rectum 18% [2]. According to PDQ, surgery cures approximately 50% of patients with colon cancer, and 25% to 40% of highly selected patients with resectable liver or lung metastases; bowel obstruction or perforation and an elevated pretreatment CEA are adverse prognostic factors [1].
Adjuvant therapy. MOSAIC (2246 patients with stage II or III disease; FOLFOX4 vs LV5FU2 for 6 months): 5-year DFS 73.3% vs 67.4% (HR 0.80); 6-year OS in stage III 72.9% vs 68.7% (HR 0.80; P=0.023), with no OS difference in stage II [3]. IDEA (12,834 patients with stage III disease in 6 trials): non-inferiority of 3 months was not confirmed in the overall population (HR 1.07; 95% CI 1.00 to 1.15) but was for CAPOX (HR 0.95); in T1–3 N1, 3-year DFS was 83.1% with 3 months vs 83.3% with 6 months, and in T4 and/or N2, 6 months was superior (64.4% vs 62.7%) [4]. ESMO 2020: CAPOX for 3 or 6 months or FOLFOX for 6 months according to risk; MSI/MMR status should be determined in stage II; adjuvant therapy preferably started within 8 weeks of surgery [5]. CHALLENGE (889 patients after adjuvant therapy; median follow-up 7.9 years): a 3-year structured exercise programme improved DFS (HR 0.72; 5-year 80.3% vs 73.9%), and 8-year OS was 90.3% vs 83.2% (HR for death 0.63) [12].
Metastatic disease by biomarker. KEYNOTE-177 (MSI-H/dMMR, first line; median follow-up 44.5 months): median PFS 16.5 months with pembrolizumab vs 8.2 months with chemotherapy (HR 0.59); median OS not reached vs 36.7 months (HR 0.74; P=0.036, short of the prespecified significance threshold; 60% crossover); grade ≥3 adverse events 22% vs 66% [7]. CheckMate 8HW (first line): 24-month PFS 72% with nivolumab + ipilimumab vs 14% with chemotherapy; grade 3 or 4 adverse events 23% vs 48% [8]. ESMO 2026 recommends nivolumab–ipilimumab in dMMR/MSI-H disease and pembrolizumab when dual checkpoint blockade is not feasible [6]. BREAKWATER (BRAF V600E, first line): encorafenib + cetuximab + mFOLFOX6 vs standard care, median PFS 12.8 vs 7.1 months (HR 0.53) and median OS 30.3 vs 15.1 months (HR 0.49) [9].
Rectal cancer. OPRA (324 patients with stage II/III disease treated with TNT; median follow-up 5.1 years): 5-year DFS 71% (induction) and 69% (consolidation); TME-free survival 39% vs 54% (P=0.012); 94% of regrowths occurred within 2 years and 99% within 3 years; DFS after TME for regrowth equalled DFS after TME at restaging (64% and 64%) [10]. ESMO 2025: TNT for high-risk tumours of the middle and lower third; watch and wait for clinical complete response, with MRI, endoscopy and DRE every 3 months for the first 2 years and every 6 months thereafter; dostarlimab with a planned duration of 6 months for locally advanced dMMR/MSI-H tumours (not FDA/EMA-approved at the time of the guideline) [11]. On 19 October 2026 the FDA granted accelerated approval to dostarlimab for stage II/III MSI-H/dMMR locally advanced rectal cancer (AZUR-1, single arm, 154 patients; 12-month clinical complete response 47% by independent central review in 116 evaluable patients) [13]. Regimens: CAPOX, FOLFOX and RAPIDO.
Scientific evidence
Scientific evidence
10 itemsImproved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
Related cancer types
Related questions
References
13 referencesShow all references, 11 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
- 3
- 4
- 5
- 6
- 7Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
- 8Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
- 9
- 10
- 11
- 12
- 13FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/questions/is-colorectal-cancer-curable/